Rhythm Pharmaceuticals' Q2 revenue rose to $29.1 million, driven by global sales of Imcivree, its treatment for rare genetic obesity disorders. The company's cash and investments totaled $319 million ...
Rhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market ...
Miracle Stars,' is set to launch on July 2, marking the series' return after 11 years. (以下引用) The release date for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results